Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact GlobeNewswire - Wed Jul 8, 8:08AM CDT

NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report , detailing the company's work on behalf of patients and families living...

RARE : 26.90 (-0.44%)
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors GlobeNewswire - Tue Jun 23, 7:00AM CDT

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or “the Company”), a biotechnology company pioneering the development of targeted genetic...

CLDI : 0.1055 (+0.48%)
LEGN : 22.66 (-3.70%)
RARE : 26.90 (-0.44%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Jun 19, 3:30PM CDT

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 26.90 (-0.44%)
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm PR Newswire - Thu Jun 4, 3:36PM CDT

NEW YORK , June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ:...

RARE : 26.90 (-0.44%)
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewswire - Wed Jun 3, 3:30PM CDT

NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 26.90 (-0.44%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 22, 3:30PM CDT

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...

RARE : 26.90 (-0.44%)
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference GlobeNewswire - Wed May 6, 3:30PM CDT

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious...

RARE : 26.90 (-0.44%)
Ultragenyx: Q1 Earnings Snapshot AP - Tue May 5, 3:07PM CDT

Ultragenyx: Q1 Earnings Snapshot

RARE : 26.90 (-0.44%)
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Tue May 5, 3:01PM CDT

First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760...

RARE : 26.90 (-0.44%)
Ultragenyx's Conference Call Tomorrow: Still Waiting for Gene Therapy to Pay Rent Barchart - Mon May 4, 4:26PM CDT

Barchart Research What to Expect from RARE Earnings RARE Generated May 4, 2026 Current Price $24.81 EPS Estimate $$-1.55 Consensus Rating Strong Buy Average Move 5.39% Ultragenyx's Conference Call Tomorrow:...

RARE : 26.90 (-0.44%)

Barchart Exclusives

CBRS Stock Alert: What to Know as Cerebras Teams Up With AMD Barchart - 11 minutes ago
Cerebras stock inches higher on a strategic partnership with AMD. Here’s what the announced deal means for CBRS shares and AMD stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.